STOCK TITAN

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

ADC Therapeutics announced the grant of options to purchase 42,000 common shares to two new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, subject to continued employment.

ADC Therapeutics ha annunciato il conferimento di opzioni per l'acquisto di 42.000 azioni ordinarie a due nuovi dipendenti come incentivo all'assunzione. I conferimenti, approvati dal Comitato per la Compensazione nell'ambito del Piano di Induzione della Società, matureranno nell'arco di quattro anni, con il 25% che si maturerà al primo anniversario e 1/48 mensilmente da quel momento fino alla maturazione completa al quarto anniversario, a condizione di mantenere il rapporto di lavoro.

ADC Therapeutics anunció la concesión de opciones para comprar 42,000 acciones ordinarias a dos nuevos empleados como un incentivo de empleo. Las concesiones, aprobadas por el Comité de Compensación bajo el Plan de Inducción de la Compañía, se consolidarán durante cuatro años, con un 25% que se consolidará en el primer aniversario y 1/48 mensualmente a partir de entonces hasta la consolidación completa en el cuarto aniversario, sujeto a la continuidad del empleo.

ADC Therapeutics는 두 명의 신규 직원에게 채용 유인으로 42,000주 일반 주식 매입 옵션을 부여했다고 발표했습니다. 이 부여는 회사의 유인 계획에 따라 보상위원회에서 승인되었으며, 4년에 걸쳐 분할되어 지급됩니다. 첫 번째 기념일에 25%가 분배되고 이후 매달 1/48씩 지급되어 네 번째 기념일에 전체 지급이 완료됩니다. 이는 계속 근무하는 것을 전제로 합니다.

ADC Therapeutics a annoncé l'octroi d'options d'achat de 42 000 actions ordinaires à deux nouveaux employés comme incitation à l'embauche. Les attributions, approuvées par le Comité de Rémunération dans le cadre du Plan d'Incitation de la Société, seront acquises sur quatre ans, avec 25% acquérant le droit au premier anniversaire et 1/48 chaque mois par la suite jusqu'à l'acquisition complète au quatrième anniversaire, sous réserve de la poursuite de l'emploi.

ADC Therapeutics gab die Gewährung von Optionen zum Kauf von 42.000 Stammaktien an zwei neue Mitarbeiter als Einstellungsmotiv bekannt. Die Gewährungen, die vom Vergütungsausschuss im Rahmen des Unternehmens-Induktionsplans genehmigt wurden, werden über vier Jahre hinweg gestaffelt, wobei 25% am ersten Jahrestag und 1/48 monatlich danach bis zur vollständigen Vesting am vierten Jahrestag fällig wird, vorausgesetzt, der Beschäftigungsverhältnis bleibt bestehen.

Positive
  • Ability to attract new talent with stock-based compensation
  • Implementation of structured employee retention program through four-year vesting schedule
Negative
  • Potential shareholder dilution from 42,000 new stock options

LAUSANNE, Switzerland, Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 42,000 of the Company's common shares to two new employees on November 1, 2024 (each, a "Grant").

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302294232.html

SOURCE ADC Therapeutics SA

FAQ

How many stock options did ADC Therapeutics (ADCT) grant on November 1, 2024?

ADC Therapeutics granted options to purchase 42,000 common shares to two new employees.

What is the vesting schedule for ADCT's November 2024 stock option grants?

The options vest 25% after one year, followed by 1/48th monthly thereafter, becoming fully vested after four years of continued employment.

Under which rule did ADC Therapeutics (ADCT) issue these stock options?

The grants were made under NYSE's Listed Company Manual Rule 303A.08, using the employment inducement exemption.

ADC Therapeutics SA

NYSE:ADCT

ADCT Rankings

ADCT Latest News

ADCT Stock Data

292.00M
96.69M
21.03%
59.19%
3.63%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EPALINGES